Antibacterial drugs are majorly used in treatment and prevention of infectious diseases and are categorized into seven major classes based on their molecular structure namely, aminoglycosides, β-Lactams, tetracyclines, sulfonamides, quinolones, macrolides, and phenicols.
The global antibacterial drugs market is estimated to account for US$ 42,048.3 Mn in terms of value IN 2020 and is expected to reach US$ 44,063.3 Mn by the end of 2027.
Global Antibacterial Drugs Market: Drivers
Increasing prevalence of bacterial infections is expected to propel growth of the global antibacterial drugs market over the forecast period. For instance, according to the study, ‘Prevalence of bacterial vaginosis and associated risk factors in pregnant women receiving antenatal care at the Kumba Health District (KHD), Cameroon’, published in May 2019, the prevalence of bacterial vaginosis was 26.2% in the study population.
Request for Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/177
Moreover, increasing approval and launch of new antibacterial drugs is also expected to aid in growth of the market. For instance, in November 2019, Shionogi Inc. received the U.S. Food and Drug Administration approval for its Fetroja (cefiderocol), an antibacterial drug for treatment of complicated urinary tract infections in patients 18 years of age or older.
β-lactams held dominant position in the global antibacterial drugs market in 2019, accounting for 59.3% share in terms of value, followed by Quinolones and Macrolides, respectively.
Global Antibacterial Drugs Market: Restraints
Increasing number of multi-drug resistant bacterial strains is expected to hinder growth of the market. Excessive usage of various antibacterial drugs has led to evolution of various multi-drug resistant bacterial strains such as vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum β-lactamase (ESBLs), MDR Escherichia coli, MDR Klebsiella pneumoniae, MDR Acinetobacter baumannii, MDR Pseudomonas aeruginosa, and MDR Enterococcus faecium.
Moreover, failure of current antibiotic discovery model in delivering new agents in order to contain present levels of antibiotic resistance is also expected to limit growth of the market.
Global Antibacterial Drugs Market: Opportunities
Pharmaceutical companies have failed to deliver significant number of new antibacterial drugs. In the future, companies need to adopt collaboration and partnership strategies for R&D on new antibacterial drugs.
Moreover, investment in the R&D of previously characterized lead compounds that did not commercialize is also expected to aid in growth of the market. With improved technology and expertise, the failed candidates can be safe and efficacious antibacterial drugs.
The global antibacterial drugs market was valued at US$ 41,780.2 Mn in 2019 and is forecast to reach a value of US$ 44,063.3 Mn by 2027 at a CAGR of 0.7% between 2020 and 2027.
Market Trends/Key Takeaways
Loss of patent and marketing exclusivity of antibacterial drugs has led to generic drug manufacturers introducing their own version of antibacterial drugs in the market. These off-patent molecules have attracted a large number of manufacturers and today account for a sizeable portion of the global antibacterial drugs market.
R&D in drug-resistant bacteria is expected to propel growth of the global antibacterial drugs market. For instance, in November 2019, researchers from Northeastern University, Boston, U.S., reported development of a new antibiotic darobactin that selectively eliminates Gram-negative pathogens.
Global Antibacterial Drugs Market: Competitive Landscape
Major players operating in the global antibacterial drugs market include Shionogi Inc, Iterum Therapeutics plc, Kyorin Pharmaceutical Co., Ltd., Allecra Therapeutics GmbH, Wockhardt Ltd., Theravance Biopharma, Inc., R-Pharm Group, Entasis Therapeutics, Melinta Therapeutics, Micurx Pharmaceutical Inc., Debiopharm Group, Boston Pharmaceuticals Inc., TenNor Therapeutics, Sichuan Pharmaceutical Co., Ltd., NacuGen Therapeutics Inc., VenatoRx Pharmaceuticals, Inc., Spero Therapeutics, GlaxoSmithKline plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi.
To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/177
Global Antibacterial Drugs Market: Key Developments
Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in September 2019, Kyorin Pharmaceutical Co., Ltd. received approval to market the oral quinolone antibacterial drug Lasvic Tablets 75mg, for the treatment of respiratory and ENT infections, from the Ministry of Health, Labor and Welfare, Japan.
Major players in the market are also focused on R&D of new antibacterial drugs. For instance, in October 2018, Iterum Therapeutics plc presented data on sulopenem, its novel oral and IV penem antibiotic at IDWeek 2018 in San Francisco, U.S.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: [email protected]